Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Cyclophilin A (CYPA)
PPIA; CyP-A; CYPH; Peptidylprolyl Isomerase A; Peptidyl-Prolyl Isomerase A; Peptidyl-prolyl cis-trans isomerase A; Cyclosporin A-binding protein
- Product No.SEA979Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range1.25-80ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.49ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 441
For more details, please contact local distributors! US$ 630 US$ 2835 US$ 5355 US$ 44100
Specificity
This assay has high sensitivity and excellent specificity for detection of Cyclophilin A (CYPA).
No significant cross-reactivity or interference between Cyclophilin A (CYPA) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Cyclophilin A (CYPA) and the recovery rates were calculated by comparing the measured value to the expected amount of Cyclophilin A (CYPA) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 85-99 | 89 |
EDTA plasma(n=5) | 96-105 | 101 |
heparin plasma(n=5) | 80-101 | 95 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cyclophilin A (CYPA) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cyclophilin A (CYPA) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cyclophilin A (CYPA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 83-98% | 95-104% | 90-104% | 86-102% |
EDTA plasma(n=5) | 96-103% | 87-95% | 91-98% | 86-98% |
heparin plasma(n=5) | 95-104% | 88-102% | 81-102% | 91-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
Atherosclerosis | EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation PubMed: 19758589 |
Biomarkers | Cyclophilin-A: a novel biomarker for untreated male essential hypertension Pubmed: 24164594 |
Cardiovascular Diabetology | Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease Pubmed:24502618 |
International Journal of Biological Sciences | Decrease in Plasma Cyclophilin A Concentration at 1 Month after Myocardial Infarction Predicts Better Left Ventricular Performance and Synchronicity at 6 Months: A Pilot Study in Patients with ST Elevation Myocardial Infarction Pubmed:25552928 |
Medicine | Cyclophilin A in Ruptured Intracranial Aneurysm PubMed: 26426668 |
Mol Cell Biochem | PPIA rs6850: A> G single-nucleotide polymorphism is associated with raised plasma cyclophilin A levels in patients with coronary artery disease PubMed: 26702934 |
Medicine (Baltimore) | Urinary Cyclophilin A as a New Marker for Diabetic Nephropathy: A Cross-Sectional Analysis of Diabetes Mellitus PubMed: 26496315 |
International Journal of Cardiology | Cyclophilin A modulates bone marrow-derived CD117(+) cells and enhances ischemia-induced angiogenesisvia the SDF-1/CXCR4 axis. Pubmed:27057951 |
Clinica Chimica Acta | Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor pubmed:27823952 |
Cardiovascular Diabetology | Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus. pubmed:27809851 |
Clinical Science | Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activity Pubmed:29382697 |
Journal of Molecular Histology | Cyclophilin a increases CD68 cell infiltration in rat experimental periodontitis Pubmed:29318411 |
Free Radical Research | Cyclophilin A and CD147 associate with progression of diabetic nephropathy Pubmed: 30572748 |
The Kaohsiung Journal of Medical Sciences | Association of cyclophilin A level and pulse pressure in predicting recurrence of cerebral infarction Pubmed: 31670477 |
Cells. | Cyclophilin A/EMMPRIN Axis Is Involved in Pro-Fibrotic Processes Associated with Thoracic Aortic Aneurysm of Marfan Syndrome Patients Pubmed: 31936351 |
JAMA Neurology | APPENDIX A: Relationship between cyclophilin A levels and matrix metalloproteinase-9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers … Pubmed: 24030206 |
Menoufia Medical Journal | Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy |
Toxins | Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy 34437430 |
Cell Death & Disease | Proteomic analysis reveals USP7 as a novel regulator of palmitic acid-induced hepatocellular carcinoma cell death Pubmed:35732625 |